These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30978288)

  • 1. A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
    Roy SM; Minasov G; Arancio O; Chico LW; Van Eldik LJ; Anderson WF; Pelletier JC; Watterson DM
    J Med Chem; 2019 Jun; 62(11):5298-5311. PubMed ID: 30978288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
    Roy SM; Grum-Tokars VL; Schavocky JP; Saeed F; Staniszewski A; Teich AF; Arancio O; Bachstetter AD; Webster SJ; Van Eldik LJ; Minasov G; Anderson WF; Pelletier JC; Watterson DM
    ACS Chem Neurosci; 2015 Apr; 6(4):666-80. PubMed ID: 25676389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.
    Zhou Z; Bachstetter AD; Späni CB; Roy SM; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2017 Apr; 14(1):75. PubMed ID: 28381303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.
    Watterson DM; Grum-Tokars VL; Roy SM; Schavocky JP; Bradaric BD; Bachstetter AD; Xing B; Dimayuga E; Saeed F; Zhang H; Staniszewski A; Pelletier JC; Minasov G; Anderson WF; Arancio O; Van Eldik LJ
    PLoS One; 2013; 8(6):e66226. PubMed ID: 23840427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
    Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
    J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to "A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction".
    Roy SM; Minasov G; Arancio O; Chico LW; Van Eldik LJ; Anderson WF; Pelletier JC; Watterson DM
    J Med Chem; 2020 Aug; 63(15):8649. PubMed ID: 32672466
    [No Abstract]   [Full Text] [Related]  

  • 7. A Novel and Selective p38 Mitogen-Activated Protein Kinase Inhibitor Attenuates LPS-Induced Neuroinflammation in BV2 Microglia and a Mouse Model.
    Gee MS; Kim SW; Kim N; Lee SJ; Oh MS; Jin HK; Bae JS; Inn KS; Kim NJ; Lee JK
    Neurochem Res; 2018 Dec; 43(12):2362-2371. PubMed ID: 30327995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
    Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL
    Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marine-derived protein kinase inhibitors for neuroinflammatory diseases.
    Ning C; Wang HD; Gao R; Chang YC; Hu F; Meng X; Huang SY
    Biomed Eng Online; 2018 Apr; 17(1):46. PubMed ID: 29690896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
    Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
    Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders.
    Bhattacharya A; Ceusters M
    Neuropsychopharmacology; 2020 Jan; 45(1):234-235. PubMed ID: 31477815
    [No Abstract]   [Full Text] [Related]  

  • 12. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008.
    Pettus LH; Wurz RP
    Curr Top Med Chem; 2008; 8(16):1452-67. PubMed ID: 18991731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies.
    Gangwal RP; Bhadauriya A; Damre MV; Dhoke GV; Sangamwar AT
    Curr Top Med Chem; 2013; 13(9):1015-35. PubMed ID: 23651481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
    Bauer SM; Kubiak JM; Rothbauer U; Laufer S
    Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity.
    Awadallah FM; Abou-Seri SM; Abdulla MM; Georgey HH
    Eur J Med Chem; 2015 Apr; 94():397-404. PubMed ID: 25778995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
    Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
    J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice.
    Ahmad A; Ali T; Park HY; Badshah H; Rehman SU; Kim MO
    Mol Neurobiol; 2017 Apr; 54(3):2269-2285. PubMed ID: 26944285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.